Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Clinical Genitourinary Cancer|August 7, 2021
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy TrialsOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Cancer Medicine|February 13, 2025
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell CarcinomaOmar Alhalabi, Mohamed A Gouda, Denái R Milton, et al.
Molecular Cancer Research : MCR|December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient OutcomesOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
The Oncologist|August 18, 2022
Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell CarcinomasJonathan Thouvenin, Omar Alhalabi, Maria Carlo, et al.
European Urology Oncology|October 13, 2023
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary TractOmar Alhalabi, Nathaniel Wilson, Lianchun Xiao, et al.
The Journal of Clinical Investigation|January 30, 2018
Factor XII and uPAR upregulate neutrophil functions to influence wound healingEvi X Stavrou, Chao Fang, Kara L Bane, et al.
Nature Communications|September 24, 2021
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapyGuangchun Han, Guoliang Yang, Dapeng Hao, et al.
European Urology Oncology|November 18, 2021
Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial CancerOmar Alhalabi, Yueting Zhu, Ameer Hamza, et al.
The Lancet. Oncology|September 7, 2025
Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trialChad Tang, Alexander D Sherry, Aaron Seo, et al.
Nature Medicine|October 13, 2020
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinomaJianjun Gao, Neema Navai, Omar Alhalabi, et al.
Pageof 8